A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

NCT02333370 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Interventions

DRUG: LEE011
DRUG: Letrozole
DRUG: Tamoxifen
DRUG: Fulvestrant
DRUG: goserelin

Sponsor

Novartis Pharmaceuticals